Recent 8-K filings for MBRX

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 13, 2026 12:00 UTC other_material item 7.01item 9.01

  Moleculin reports preliminary blinded CR rate ~30% in MIRACLE trial; first unblinding before June 30

• May 12, 2026 13:30 UTC other_material item 7.01item 9.01

  Moleculin reports Annamycin shows no clinically significant cardiotoxicity in 90-patient pooled analysis

source · MBRX on sec.gov